Citigroup Inc Rx Sight, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Rx Sight, Inc. stock. As of the latest transaction made, Citigroup Inc holds 26,841 shares of RXST stock, worth $922,793. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,841

Previous 24,490 9.6%

Holding current value

$922,793

Previous $1.47 Million 9.98%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$40.78 - $57.04 $95,873 - $134,101	2,351 Added 9.6%	26,841 $1.33 Million
Q2 2024 Aug 12, 2024	BUY	$50.42 - $64.29 $421,158 - $537,014	8,353 Added 51.76%	24,490 $1.47 Million
Q1 2024 May 10, 2024	BUY	$35.51 - $57.92 $61,041 - $99,564	1,719 Added 11.92%	16,137 $832,000
Q4 2023 Feb 09, 2024	BUY	$20.91 - $40.9 $300,183 - $587,160	14,356 Added 23154.84%	14,418 $581,000
Q3 2023 Nov 09, 2023	SELL	$27.05 - $33.37 $542,433 - $669,168	-20,053 Reduced 99.69%	62 $1,000
Q2 2023 Aug 10, 2023	BUY	$16.37 - $28.9 $329,086 - $580,976	20,103 Added 167525.0%	20,115 $579,000
Q1 2023 May 11, 2023	SELL	$12.58 - $16.68 $1,597 - $2,118	-127 Reduced 91.37%	12 $0
Q4 2022 Feb 09, 2023	SELL	$9.93 - $14.2 $1,707 - $2,442	-172 Reduced 55.31%	139 $1,000
Q3 2022 Nov 10, 2022	SELL	$11.19 - $15.85 $11,391 - $16,135	-1,018 Reduced 76.6%	311 $4,000
Q2 2022 Aug 10, 2022	BUY	$10.61 - $16.66 $7,172 - $11,262	676 Added 103.52%	1,329 $19,000
Q1 2022 May 12, 2022	SELL	$8.97 - $14.03 $12,755 - $19,950	-1,422 Reduced 68.53%	653 $8,000
Q4 2021 Feb 10, 2022	BUY	$9.52 - $13.81 $10,729 - $15,563	1,127 Added 118.88%	2,075 $23,000
Q3 2021 Nov 10, 2021	BUY	$11.85 - $17.32 $11,233 - $16,419	948 New	948 $12,000

Others Institutions Holding RXST

# of Institutions

224

Shares Held

32.3M

Call Options Held

394K

Put Options Held

32K

View Full List

About RxSight, Inc.

Ticker RXST
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 27,638,900
Market Cap $950M
Description
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...

More about RXST

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account